» Articles » PMID: 33753742

The Oncogene Mct-1 Promotes Progression of Hepatocellular Carcinoma Via Enhancement of Yap-mediated Cell Proliferation

Overview
Date 2021 Mar 23
PMID 33753742
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Malignant T-cell-amplified sequence 1 (Mct-1) has been reported as an oncogene in multiple malignant diseases. However, the function of Mct-1 in hepatocellular carcinoma (HCC) and the molecular mechanisms underlying tumor progression have not been explored. In this study, Mct-1 expression levels in HCC tissues and cells were detected by quantitative real-time PCR and western blotting. Mct-1 shRNAs and overexpression vector were transfected into HCC cells to downregulate or upregulate Mct-1 expression. In vitro and in vivo assays were performed to investigate the function of Mct-1 in cell proliferation and apoptosis. RNA sequencing analysis (RNA-seq) was performed to explore differences in gene expression when silenced Mct-1 expression. Mct-1 was upregulated in HCC specimens and cell lines, and higher expression of Mct-1 was predictive of poor survival. Overexpression of Mct-1 was shown to promote cell proliferation and repress cell apoptosis both in vitro and in vivo. The results of RNA-seq indicated that knockdown of Mct-1 suppressed Yap expression, while the results of the luciferase assay also revealed that Mct-1 increases the activity of the Yap promoter. Restoration of Yap expression in Mct-1 knockdown cells partially recovered the promotion of cell proliferation and inhibition of apoptosis. Collectively, these results indicate that Mct-1 acts as a tumor promoter gene in HCC progression by up-regulating Yap expression and, thus, could serve a novel potential diagnostic and prognostic biomarker for HCC.

Citing Articles

A comprehensive analysis of the FOX family for predicting kidney renal clear cell carcinoma prognosis and the oncogenic role of FOXG1.

Yang W, Chen H, Ma L, Dong J, Wei M, Xue X Aging (Albany NY). 2022; 14(24):10107-10124.

PMID: 36585925 PMC: 9831721. DOI: 10.18632/aging.204448.

References
1.
Hsu H, Shi B, Gartenhaus R . The MCT-1 oncogene product impairs cell cycle checkpoint control and transforms human mammary epithelial cells. Oncogene. 2005; 24(31):4956-64. DOI: 10.1038/sj.onc.1208680. View

2.
Kasiappan R, Shih H, Wu M, Choy C, Lin T, Chen L . The antagonism between MCT-1 and p53 affects the tumorigenic outcomes. Mol Cancer. 2010; 9:311. PMC: 3019166. DOI: 10.1186/1476-4598-9-311. View

3.
Dey A, Varelas X, Guan K . Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine. Nat Rev Drug Discov. 2020; 19(7):480-494. PMC: 7880238. DOI: 10.1038/s41573-020-0070-z. View

4.
Nandi S, Reinert L, Hachem A, Mazan-Mamczarz K, Hagner P, He H . Phosphorylation of MCT-1 by p44/42 MAPK is required for its stabilization in response to DNA damage. Oncogene. 2006; 26(16):2283-9. DOI: 10.1038/sj.onc.1210030. View

5.
Feng J, Dai W, Mao Y, Wu L, Li J, Chen K . Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis. J Exp Clin Cancer Res. 2020; 39(1):24. PMC: 6993409. DOI: 10.1186/s13046-020-1528-x. View